应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
未开盘 07-03 16:08:13
3.380
+0.210
+6.62%
最高
3.390
最低
3.200
成交量
1.30万
今开
3.390
昨收
3.170
日振幅
5.99%
总市值
17.39亿
流通市值
17.39亿
总股本
5.15亿
成交额
4.29万
换手率
0.00%
流通股本
5.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
屡屡尝到并购甜头的新诺威,这一次却不灵了?
投资时报 · 07-03 13:43
屡屡尝到并购甜头的新诺威,这一次却不灵了?
中国创新药,门前两条路
钛媒体APP · 07-03 11:27
中国创新药,门前两条路
永泰生物-B盘中异动 早盘股价大涨6.94%报3.391港元
自选股智能写手 · 07-03 10:14
永泰生物-B盘中异动 早盘股价大涨6.94%报3.391港元
“科创板首富”冲刺港股IPO,或刷新近年创新药企上市募资纪录
独角兽早知道 · 07-03 08:10
“科创板首富”冲刺港股IPO,或刷新近年创新药企上市募资纪录
一品红(300723.SZ)拟受让广州瑞安博24.05%股权 推动创新药AR882研发上市
智通财经 · 07-02 17:20
一品红(300723.SZ)拟受让广州瑞安博24.05%股权 推动创新药AR882研发上市
复宏汉霖(02696.HK)创新药“汉斯状”获批在日本开展临床试验
阿斯达克财经 · 07-02 16:36
复宏汉霖(02696.HK)创新药“汉斯状”获批在日本开展临床试验
新华制药:公司创新药OAB-14正在按要求进行临床1期试验,目前进展顺利
每日经济新闻 · 07-02 15:29
新华制药:公司创新药OAB-14正在按要求进行临床1期试验,目前进展顺利
永泰生物-B(06978)股价显著下跌13.247%,现价港币$3.34
阿斯达克财经 · 07-02 13:24
永泰生物-B(06978)股价显著下跌13.247%,现价港币$3.34
瞄准国内创新药企“出海”需求 Veeva研发云携多款数字化产品加码中国市场
证券日报 · 07-01 15:46
瞄准国内创新药企“出海”需求 Veeva研发云携多款数字化产品加码中国市场
64%临床成功率的创新药,值得信任吗?
蓝鲸财经 · 07-01 13:25
64%临床成功率的创新药,值得信任吗?
创新药企复宏汉霖消亡史
经济观察报 · 06-29
创新药企复宏汉霖消亡史
900亿中药巨头,大动作!
中国基金报 · 06-29
900亿中药巨头,大动作!
明济生物创新药大冒险:一年50倍收益背后有窘境
经济观察报 · 06-29
明济生物创新药大冒险:一年50倍收益背后有窘境
云南白药(000538.SZ)拟引进抗体药物KA-1641相关专利 加强肿瘤创新药领域竞争力
智通财经 · 06-28
云南白药(000538.SZ)拟引进抗体药物KA-1641相关专利 加强肿瘤创新药领域竞争力
永泰生物-B(06978)股价显著上升11.821%,现价港币$3.5
阿斯达克财经 · 06-28
永泰生物-B(06978)股价显著上升11.821%,现价港币$3.5
永泰生物-B盘中异动 临近收盘股价大涨5.40%报3.300港元
自选股智能写手 · 06-28
永泰生物-B盘中异动 临近收盘股价大涨5.40%报3.300港元
创新药定价权被夺走
华尔街见闻 · 06-28
创新药定价权被夺走
中国生物制药(01177.HK)跟踪点评:股权激励彰显长期发展信心 创新药管线加速推进
西部证券 · 06-28
中国生物制药(01177.HK)跟踪点评:股权激励彰显长期发展信心 创新药管线加速推进
“中国鼠王”
重庆商报 · 06-28
“中国鼠王”
东财创新药A基金经理变动:姚楠燕不再担任该基金基金经理
证券之星 · 06-27
东财创新药A基金经理变动:姚楠燕不再担任该基金基金经理
加载更多
公司概况
公司名称:
永泰生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。
发行价格:
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.38,"timestamp":1719994093019,"preClose":3.17,"halted":0,"volume":13000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.696039,"marketStatus":"未开盘","marketStatusCode":0,"change":0.21,"latestTime":"07-03 16:08:13","open":3.39,"high":3.39,"low":3.2,"amount":42890,"amplitude":0.059937,"askPrice":3.38,"askSize":9000,"bidPrice":3.17,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.6960390397659812,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"listingDate":1594310400000,"adjPreClose":3.17,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.29148,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2448266811","title":"屡屡尝到并购甜头的新诺威,这一次却不灵了?","url":"https://stock-news.laohu8.com/highlight/detail?id=2448266811","media":"投资时报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448266811?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:43","pubTimestamp":1719985401,"startTime":"0","endTime":"0","summary":"进入2024年后,颇具并购经验的新诺威又决定将石药百克收入囊中,但这次并购并未再度掀起波澜。新诺威近日发布公告称,此次交易所涉及的尽职调查、审计、评估等各项工作仍在持续推进中。2023年9月12日,新诺威发布公告称,公司计划对石药集团巨石生物实施现金增资18.71亿元。然而,新诺威此次复牌后的走势却出人意料。2023年,新诺威营收实现25.02亿元,同比下滑4.75%,这是其上市以来年度营收首次出现下滑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031348239ef9af4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031348239ef9af4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0326950275.SGD","SG9999004220.SGD","LU0072913022.USD","LU1993786604.SGD","BK1574","IE00B543WZ88.USD","LU1807302812.USD","BK1191","01093","LU0501845795.SGD","IE0008368742.USD","IE00B5MMRT66.SGD","BK1521","LU0067412154.USD","06978","BK1161","LU1226287529.USD","LU0140636845.USD","LU0880133367.SGD","BK1515"],"gpt_icon":0},{"id":"2448675142","title":"中国创新药,门前两条路","url":"https://stock-news.laohu8.com/highlight/detail?id=2448675142","media":"钛媒体APP","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448675142?lang=zh_cn&edition=full","pubTime":"2024-07-03 11:27","pubTimestamp":1719977240,"startTime":"0","endTime":"0","summary":"文 | 医曜创新药是世界上最赚钱的产业之一,其本质就是一种专利寻租权模式。依靠专利保护,在某一适应症形成垄断,从而获得很高的药物销售价格。这种高售价实则就是“租金”,而创新药正是依靠这份租金进而创造利润。所以患者买到的创新药,大部分花费都相当于向药企支付了专利“租金”。基于此,对于药企而言,真正赚钱的...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/ONBJV4Yu88ct_V_ba67xe84T9wnPgQf4tzdfnmTumdJT0AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/ONBJV4Yu88ct_V_ba67xe84T9wnPgQf4tzdfnmTumdJT0AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240703A031UX00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240703A031UX00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2448143083","title":"永泰生物-B盘中异动 早盘股价大涨6.94%报3.391港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448143083","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448143083?lang=zh_cn&edition=full","pubTime":"2024-07-03 10:14","pubTimestamp":1719972883,"startTime":"0","endTime":"0","summary":"2024年07月03日早盘10时14分,永泰生物-B股票出现波动,股价急速拉升6.94%。截至发稿,该股报3.391港元/股,成交量3000股,换手率0.00%,振幅0.00%。资金方面,该股资金流入1.017万港元,流出0港元。永泰生物-B股票所在的生物技术行业中,整体跌幅为0.08%。永泰生物-B公司简介:永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031014449681906f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031014449681906f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2448119793","title":"“科创板首富”冲刺港股IPO,或刷新近年创新药企上市募资纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2448119793","media":"独角兽早知道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448119793?lang=zh_cn&edition=full","pubTime":"2024-07-03 08:10","pubTimestamp":1719965400,"startTime":"0","endTime":"0","summary":"2023年1月,百利天恒登陆科创板,如果公司顺利在今年完成香港IPO,这意味着公司在短短两年时间里实现A+H两地上市。此外,公司积极筹备赴港IPO,也是对国家相关政策的积极响应。据悉,上述交易刷新了全球ADC类药物单品交易总价的纪录,也创下国内创新药License out交易的首付款及总交易额双项纪录,是我国首款成功“出海”的双抗ADC新药。最新消息显示,2024年3月份,百利天恒已收到由BMS支付的8亿美元首付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2024-07-03/doc-incavckv6741912.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2024-07-03/doc-incavckv6741912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","HSCEI","07226","159982","159992","BK1574","BK1161","HSTECH","YANG"],"gpt_icon":0},{"id":"2448138604","title":"一品红(300723.SZ)拟受让广州瑞安博24.05%股权 推动创新药AR882研发上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2448138604","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448138604?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:20","pubTimestamp":1719912031,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)公告,公司拟受让控股子公司广州瑞安博少数股东部分股权,由公司全资子公司瑞奥生物以自有资金1000万美元受让控股子公司广州瑞安博少数股东Arthrosi 24.05%的股权,并签订《股权转让协议》。交易完成后,公司全资子公司瑞奥生物持有广州瑞安博的股权比例将从60.70%上升至84.75%,广州瑞安博仍为公司控股子公司。据悉,该事项旨在推动创新药AR882高效研发和快速上市,进一步提高公司核心竞争力和综合竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159992","BK4534","BK4567","300723","BK4171","BK4585","BK4588","BK0239","BK4224","PLD","BK1161","06978"],"gpt_icon":0},{"id":"2448187873","title":"复宏汉霖(02696.HK)创新药“汉斯状”获批在日本开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2448187873","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448187873?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:36","pubTimestamp":1719909360,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 宣布,公司自主开发的创新药物汉斯状近日获国际多中心3期临床试验通知获得默示许可,相关临床试验可以在日本开展。汉斯状主要用作治疗转移性结直肠癌,已于2022年3月获批在内地上市,亦获准在印尼上市,其在于欧盟的上市许可申请亦获得欧洲药品管理局受理,在美国桥接试验正稳步推进中。(vc/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1360828/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","06978","BK1141","03347","BK1576","159992","BK1583","02696"],"gpt_icon":0},{"id":"2448166186","title":"新华制药:公司创新药OAB-14正在按要求进行临床1期试验,目前进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2448166186","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448166186?lang=zh_cn&edition=full","pubTime":"2024-07-02 15:29","pubTimestamp":1719905353,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:公司在阿兹海默症研究方面有何进展顺利吗?公司都代工和生产哪些维生素产品新华制药(000756.SZ)7月2日在投资者互动平台表示,公司创新药OAB-14正在按要求进行临床1期试验,目前进展顺利。公司产品名录请参阅公司官网(记者 蔡鼎)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021529279564dd9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021529279564dd9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1515","BK1191","BK1161","00719","BK1574"],"gpt_icon":0},{"id":"2448990427","title":"永泰生物-B(06978)股价显著下跌13.247%,现价港币$3.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2448990427","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448990427?lang=zh_cn&edition=full","pubTime":"2024-07-02 13:24","pubTimestamp":1719897840,"startTime":"0","endTime":"0","summary":"[下跌股]永泰生物-B(06978) 股价在下午01:24比前收市价显著下跌13.247%,现股价为港币$3.34。至目前为止,今日最高价为$3.77,而最低价为$3.34。总成交量为3.7万股,总成交金额为港币$13.133万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407021460/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2448950435","title":"瞄准国内创新药企“出海”需求 Veeva研发云携多款数字化产品加码中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2448950435","media":"证券日报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448950435?lang=zh_cn&edition=full","pubTime":"2024-07-01 15:46","pubTimestamp":1719819973,"startTime":"0","endTime":"0","summary":"瞄准国内创新药企“出海”需求 Veeva研发云携多款数字化产品加码中国市场","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407013118366316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK1574","BK1161","YINN","BK4585","06978"],"gpt_icon":0},{"id":"2448955792","title":"64%临床成功率的创新药,值得信任吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2448955792","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448955792?lang=zh_cn&edition=full","pubTime":"2024-07-01 13:25","pubTimestamp":1719811502,"startTime":"0","endTime":"0","summary":"一生九死,是对创新药研发最好的概括。根据BIO等组织发布的关于药物临床开发成功率的报告,其在统计完9704个药物的1.27万个临床开发项目后发现,2011年至2020年十年间,药物开发项目从1期临床到获得FDA批准上市的成功率平均为7.9%,所需要的时间平均为10.5年。RNAi领头羊Alnylam的临床转化成功率高达64.3%,并且,目前全球获批的5款RNAi药物原研皆出自Alnylam之手。换句话说,Alnylam超高的临床成功率背后,既离不开RNAi药物机制的本身优势,更离不开自身的奋斗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/234357","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2447964436","title":"创新药企复宏汉霖消亡史","url":"https://stock-news.laohu8.com/highlight/detail?id=2447964436","media":"经济观察报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447964436?lang=zh_cn&edition=full","pubTime":"2024-06-29 16:59","pubTimestamp":1719651548,"startTime":"0","endTime":"0","summary":"经济观察网 记者 瞿依贤 复宏汉霖,这家港股18A创新药企中首家实现盈利的公司,即将成为历史。6月24日,停牌一个月后的复宏汉霖(02696.HK)和其控股股东复星医药(600196.SH/02196.HK)联合发了一则公告:复星医药旗下控股子公司复星新药拟以吸收合并方式对复宏汉霖私有化,交易价格不超过54.07亿港元。在吸收合并交易前,...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/Oy-zuiMTJnZxBibJKsbdBv5scrcOUI6I3Ail5ST9inddUAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Oy-zuiMTJnZxBibJKsbdBv5scrcOUI6I3Ail5ST9inddUAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240629A061QR00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240629A061QR00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1161","02696","BK1574","06978"],"gpt_icon":0},{"id":"2447166278","title":"900亿中药巨头,大动作!","url":"https://stock-news.laohu8.com/highlight/detail?id=2447166278","media":"中国基金报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447166278?lang=zh_cn&edition=full","pubTime":"2024-06-29 13:33","pubTimestamp":1719639180,"startTime":"0","endTime":"0","summary":"云南白药6月28日晚公告,公司拟引进抗体药物KA-1641的相关专利,并将在全球范围内对该产品进行研究开发、生产和商业化活动。此外,云南白药还将与北京昭衍生物技术有限公司及康源博创签订三方协议,由昭衍生物作为医药合同定制研发生产机构负责生产和直接供应。早在2020年8月,片仔癀自主开发的首个化学1类创新药PZH2111片便获得国家药监局批准开展临床试验,主要用于治疗FGFR基因改变的肝内胆管细胞癌、尿路上皮细胞癌等晚期实体肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656101313&idx=2&sn=46ccd77271d68c374eb44f659e00e5a4&chksm=8ada2c6919ae49ae4aaa493b4e090f493d1f7b6a41e9f9b17fbadeaf482d44e997daacb53180&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656101313&idx=2&sn=46ccd77271d68c374eb44f659e00e5a4&chksm=8ada2c6919ae49ae4aaa493b4e090f493d1f7b6a41e9f9b17fbadeaf482d44e997daacb53180&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2447666647","title":"明济生物创新药大冒险:一年50倍收益背后有窘境","url":"https://stock-news.laohu8.com/highlight/detail?id=2447666647","media":"经济观察报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447666647?lang=zh_cn&edition=full","pubTime":"2024-06-29 11:19","pubTimestamp":1719631158,"startTime":"0","endTime":"0","summary":"经济观察报 记者 张英 编者按:自2015年启动药政改革以来,经过十年的“国药维新”,中国生物医药产业已在重大药物研发前沿领域取得了长足进步,甚至在个别领域实现了领先。多个新老明星药企的实验室纷纷发现了价值不菲的药物分子。这些珍贵的药物分子,正不断突破曾被欧美跨国公司垄断的创新药物市场,未来将支撑中国药企...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OMlI_tOQxpScX6LcUIEfC9Cu3T8TCNKQfd1bBK__1xGQYAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OMlI_tOQxpScX6LcUIEfC9Cu3T8TCNKQfd1bBK__1xGQYAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240629A02WZH00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240629A02WZH00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2446097445","title":"云南白药(000538.SZ)拟引进抗体药物KA-1641相关专利 加强肿瘤创新药领域竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2446097445","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446097445?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:09","pubTimestamp":1719576598,"startTime":"0","endTime":"0","summary":"KA-1641能够与公司已有核药产品线一同加强在肿瘤创新药领域的竞争力,符合布局创新药的战略方向。以此项目为契机,能够打通抗体药物临床前研发到临床研究的研发链条,有助于后续自研或引进其他创新药物。该抗体药物竞争格局良好,未来能够与核药诊断、治疗产品一起形成具有特色的肿瘤相关产品矩阵,形成协同发展,可以充分利用未来建设的肿瘤院内渠道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK4139","000538","BK0028","BK0012","BK1161","KA","BK0196","BK0175","159992","BK0187","BK0188","BK0239","BK1574","BK0164"],"gpt_icon":0},{"id":"2446276355","title":"永泰生物-B(06978)股价显著上升11.821%,现价港币$3.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2446276355","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446276355?lang=zh_cn&edition=full","pubTime":"2024-06-28 15:55","pubTimestamp":1719561300,"startTime":"0","endTime":"0","summary":"[上升股]永泰生物-B(06978) 股价在下午03:55比前收市价显著上升11.821%,现股价为港币$3.5。至目前为止,今日最高价为$3.5,而最低价为$3.2。总成交量为4.8万股,总成交金额为港币$15.543万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406282001/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2446522926","title":"永泰生物-B盘中异动 临近收盘股价大涨5.40%报3.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446522926","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446522926?lang=zh_cn&edition=full","pubTime":"2024-06-28 15:50","pubTimestamp":1719561051,"startTime":"0","endTime":"0","summary":"2024年06月28日临近收盘15时50分,永泰生物-B股票出现波动,股价急速拉升5.40%。截至发稿,该股报3.300港元/股,成交量4.2万股,换手率0.01%,振幅2.24%。资金方面,该股资金流入12.205万港元,流出1.288万港元。永泰生物-B股票所在的生物技术行业中,整体涨幅为0.11%。永泰生物-B公司简介:永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628155051aef71374&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628155051aef71374&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2446451875","title":"创新药定价权被夺走","url":"https://stock-news.laohu8.com/highlight/detail?id=2446451875","media":"华尔街见闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446451875?lang=zh_cn&edition=full","pubTime":"2024-06-28 11:35","pubTimestamp":1719545732,"startTime":"0","endTime":"0","summary":"发展史仅有10年的国产创新药,已经由BD通路打开一扇透气的窗口。随着海外生物科技资产越来越贵,国内创新疗法性价比凸显,将继续吸引MNC抄底,国内FIC或BIC潜力的管线资产,只要愿意卖,都一定会被MNC买走,在国际市场上获得合理定价。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/06bec2d4-3690-4ec8-8e7f-38ed95c04b6f.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/06bec2d4-3690-4ec8-8e7f-38ed95c04b6f.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3718317","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3718317","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2446510005","title":"中国生物制药(01177.HK)跟踪点评:股权激励彰显长期发展信心 创新药管线加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2446510005","media":"西部证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446510005?lang=zh_cn&edition=full","pubTime":"2024-06-28 10:35","pubTimestamp":1719542114,"startTime":"0","endTime":"0","summary":"事件:近期公告计划实施上市以来首次股份激励计划旗下子公司正大天晴计划使用不超过10 亿人民币的自有资金市场回购股份,激励对象包括中高层管理人员及同级别专业人员等;6 月5 日至6 月20 日期间,公司已回购约0.95 亿港元用于后续股份激励计划。加大研发投入,新药管线不断推进。夯实四大治疗领域优势,股权激励彰显信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406281035199f6e0c09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406281035199f6e0c09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","BK1515","BK1589","BK1521","01177","BK1161","BK1191"],"gpt_icon":0},{"id":"2446565797","title":"“中国鼠王”","url":"https://stock-news.laohu8.com/highlight/detail?id=2446565797","media":"重庆商报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446565797?lang=zh_cn&edition=full","pubTime":"2024-06-28 00:00","pubTimestamp":1719504000,"startTime":"0","endTime":"0","summary":"百奥赛图之所以能成为“中国鼠王”,跟公司创始人沈月雷的“疯狂”有着直接关联。在沈月雷的概念中,百奥赛图所做的事远不止一只“小白鼠”。2023年,百奥赛图在销售额上成为“国内模式动物三巨头”之首,前一年完成港交所挂牌上市之后,又开始筹备在科创板挂牌。但一开始,国际药企客户普遍认为中国动物房“不干净”。“千鼠万抗”应运而生2020年到2023年,公司的对外业务量受到巨大影响,沈","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062801063795df0151&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062801063795df0151&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315","BK1574","06978"],"gpt_icon":0},{"id":"2446324824","title":"东财创新药A基金经理变动:姚楠燕不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2446324824","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446324824?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:31","pubTimestamp":1719451877,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年6月27日,东财中证沪港深创新药指数发起式(014128)发布公告,姚楠燕不再担任该基金基金经理,离任日期为2024年6月27日,变更后东财中证沪港深创新药指数发起式(014128)的基金经理为吴逸。截止2024年6月26日,东财中证沪港深创新药指数发起式净值为0.5256,较上一日上涨1.62%,近一年下跌24.22%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700014150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK1574","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.1155},{"period":"1month","weight":0.0764},{"period":"3month","weight":-0.0865},{"period":"6month","weight":-0.2489},{"period":"1year","weight":-0.2318},{"period":"ytd","weight":-0.324}],"compareEarnings":[{"period":"1week","weight":-0.0062},{"period":"1month","weight":-0.0231},{"period":"3month","weight":0.0749},{"period":"6month","weight":0.0873},{"period":"1year","weight":-0.074},{"period":"ytd","weight":0.0546}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.129933},{"month":2,"riseRate":0.5,"avgChangeRate":0.104699},{"month":3,"riseRate":0.25,"avgChangeRate":-0.117615},{"month":4,"riseRate":0.25,"avgChangeRate":-0.077145},{"month":5,"riseRate":0.5,"avgChangeRate":0.017788},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.101702},{"month":8,"riseRate":0.5,"avgChangeRate":-0.036515},{"month":9,"riseRate":0.25,"avgChangeRate":-0.028227},{"month":10,"riseRate":0.75,"avgChangeRate":0.082892},{"month":11,"riseRate":0.5,"avgChangeRate":-0.017056},{"month":12,"riseRate":0.75,"avgChangeRate":0.09355}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}